Vifor Pharma
| Vifor Pharma AG | |
|---|---|
| legal form | Corporation |
| ISIN | CH0364749348 |
| founding | 2008 |
| Seat |
St. Gallen , Switzerland
|
| management | Stefan Schulze (COO) Etienne Jornod ( Chairman of the Board of Directors ) |
| Number of employees | 2,650 |
| sales | 1,342.1 billion CHF (899 million euros ) |
| Branch | Pharma |
| Website | www.viforpharma.com |
| As of March 15, 2018 | |
The Vifor Pharma AG is a Swiss pharmaceutical company .
General
The Vifor Pharma Group - part of the former Galenica Group - is a global specialty pharmaceutical company that focuses on three areas: iron deficiency , nephrology and cardiorenal therapies.
history
The company was founded in 2008 with the takeover of the former Aspreva Pharmaceuticals as a business unit of the Galenica Group. Under this roof, the former companies in the pharmaceutical division of Galenica - Vifor (International), Vifor and Potters - have been merged into a fully integrated pharmaceutical company. In September 2009, Galenica acquired OM Pharma, a pharmaceutical company active in the field of immunology . The US company Relypsa was acquired by Galenica in September 2016 and integrated into Vifor Pharma.
In August 2014, Galenica was split organizationally into the Vifor Pharma and Galenica Santé divisions . The aim was to create two independent companies by going public for Galenica Santé through a public share placement (IPO). The IPO was carried out on April 7, 2017, after which the other divisions were renamed the Vifor Pharma Group on May 11, 2017 . The proceeds from the IPO are to be used, among other things, to repay the USD 1.5 billion loan that was taken out in September 2016 for the acquisition of the biotech company Relypsa.
Products
The most important product area of Vifor Pharma are iron deficiency preparations, v. a. Ferinject / Injectafer ( iron carboxymaltose ). In 2017, it turned over 604.7 million Swiss francs.
Individual evidence
- ^ Executive Committee. Vifor Pharma.
- ↑ a b c d Annual Report 2017. Vifor Pharma, 2018.
- ↑ Who we are. Vifor Pharma.
- ^ History. Vifor Pharma.
- ↑ Juliane Lutz: Galenica is committed to splitting up. In: Berner Zeitung . August 13, 2014.
- ↑ Galenica creates the basis for two listed, independent companies ( Memento from January 20, 2017 in the Internet Archive ). Galenica, August 12, 2014 (press release; PDF).
- ↑ Planned division of the Galenica Group ( memento from January 20, 2017 in the Internet Archive ). January 19, 2017 (press release; PDF; 3.8 kB).
- ↑ Annual Report 2017. Executive Message Executive Chairman. Vifor Pharma Group, 2018, p. 4 (PDF; 6.7 MB).